D. S. Heo, T. L. Whiteside, J. T. Johnson, K. N. Chen, E. L. Barnes et al., Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck, Cancer Res, vol.47, issue.23, pp.6353-6362, 1987.

K. Itoh, C. D. Platsoucas, and C. M. Balch, Autologous tumorspecific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor, J Exp Med, vol.168, issue.4, pp.1419-1441, 1988.

S. Miescher, T. L. Whiteside, N. De-tribolet, V. Fliedner, and V. , In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers, J Neurosurg, vol.68, issue.3, pp.438-448, 1988.

Y. L. Wang, L. S. Si, A. Kanbour, R. B. Herberman, and T. L. Whiteside, Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes, Cancer Res, vol.49, issue.21, pp.5979-5985, 1989.

S. M. Soudja, M. Wehbe, A. Mas, L. Chasson, C. P. De-tenbossche et al., Tumorinitiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice, Cancer Res, vol.70, issue.9, pp.3515-3525, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00507316

H. Yu, D. Pardoll, and R. Jove, STATs in cancer inflammation and immunity: a leading role for STAT3, Nat Rev Cancer, vol.9, issue.11, pp.798-809, 2009.

M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, vol.29, pp.235-271, 2011.

P. Van-der-bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De-plaen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, issue.5038, pp.1643-1647, 1991.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, vol.298, issue.5594, pp.850-854, 2002.

S. A. Rosenberg, J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes et al., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, vol.17, issue.13, pp.4550-4557, 2011.

P. Aebersold, C. Hyatt, S. Johnson, K. Hines, L. Korcak et al., Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response, J Natl Cancer Inst, vol.83, issue.13, pp.932-937, 1991.

P. F. Robbins, M. E. Dudley, J. Wunderlich, M. El-gamil, Y. F. Li et al., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy, J Immunol, vol.173, issue.12, pp.7125-7130, 2004.

M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal et al., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, J Clin Oncol, vol.26, issue.32, pp.5233-5239, 2008.

A. E. Chang and S. A. Rosenberg, Overview of interleukin-2 as an immunotherapeutic agent, Semin Surg Oncol, vol.5, issue.6, pp.385-390, 1989.

S. A. Rosenberg, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber et al., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2, JAMA, vol.271, issue.12, pp.907-913, 1994.

S. A. Rosenberg, B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian et al., Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, N Engl J Med, vol.319, issue.25, pp.1676-1680, 1988.

A. Belldegrun, L. M. Muul, and S. A. Rosenberg, Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity, Cancer Res, vol.48, issue.1, pp.206-214, 1988.

T. Nishimura, Y. Terashima, T. Hattori, M. Satoh, Y. Kondo et al., Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity, Urol Int, vol.47, issue.1, pp.83-85, 1991.

S. A. Rosenberg, J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber et al., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, J Natl Cancer Inst, vol.86, issue.15, pp.1159-1166, 1994.

S. L. Topalian, L. M. Muul, D. Solomon, and S. A. Rosenberg, Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials, J Immunol Methods, vol.102, issue.1, pp.127-141, 1987.

R. O. Dillman, R. K. Oldham, N. M. Barth, R. J. Cohen, D. R. Minor et al., , 1991.

, Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial, Cancer, vol.68, issue.1, pp.1-8

P. S. Goedegebuure, L. M. Douville, H. Li, G. C. Richmond, D. D. Schoof et al., Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study, J Clin Oncol, vol.13, issue.8, pp.1939-1949, 1995.

M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients, J Immunother, vol.26, issue.4, pp.332-342, 2003.

F. Jotereau, M. C. Pandolfino, D. Boudart, E. Diez, B. Dreno et al., LeMevel B (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, issue.6, pp.405-411, 1991.

P. Muranski, A. Boni, C. Wrzesinski, D. E. Citrin, S. A. Rosenberg et al., Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?, Nat Clin Pract Oncol, vol.3, issue.12, pp.668-681, 2006.

P. A. Prieto, K. H. Durflinger, J. R. Wunderlich, S. A. Rosenberg, and M. E. Dudley, Enrichment of CD8+ cells from melanoma tumorinfiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy, J Immunother, vol.33, issue.5, pp.547-556, 2010.

D. J. Schwartzentruber, S. S. Hom, R. Dadmarz, D. E. White, J. R. Yannelli et al., In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2, J Clin Oncol, vol.12, issue.7, pp.1475-1483, 1994.

M. J. Turk, J. A. Guevara-patino, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi et al., Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells, J Exp Med, vol.200, issue.6, pp.771-782, 2004.

L. Gattinoni, S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, J Exp Med, vol.202, issue.7, pp.907-912, 2005.

S. Yeh, N. K. Karne, S. P. Kerkar, C. K. Heller, D. C. Palmer et al., Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma, Ophthalmology, vol.116, issue.5, p.981, 2009.

M. J. Besser, R. Shapira-frommer, A. J. Treves, D. Zippel, O. Itzhaki et al., Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients, J Immunother, vol.32, issue.4, pp.415-423, 2009.

S. L. Goff, F. O. Smith, J. A. Klapper, R. Sherry, J. R. Wunderlich et al., Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL, J Immunother, vol.33, issue.8, pp.840-847, 2010.

B. Dreno, J. M. Nguyen, A. Khammari, M. C. Pandolfino, M. H. Tessier et al., Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunol Immunother, vol.51, issue.10, pp.539-546, 2002.
URL : https://hal.archives-ouvertes.fr/inserm-02482144

A. Khammari, J. M. Nguyen, M. C. Pandolfino, G. Quereux, A. Brocard et al., Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunol Immunother, vol.56, issue.11, pp.1853-1860, 2007.

N. Labarriere, M. C. Pandolfino, N. Gervois, A. Khammari, M. H. Tessier et al., Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunol Immunother, vol.51, issue.10, pp.532-538, 2002.
URL : https://hal.archives-ouvertes.fr/inserm-02482115

H. Benlalam, V. Vignard, A. Khammari, A. Bonnin, Y. Godet et al., Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunol Immunother, vol.56, issue.4, pp.515-526, 2007.

P. G. Coulie, V. Brichard, A. Van-pel, T. Wolfel, J. Schneider et al., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J Exp Med, vol.180, issue.1, pp.35-42, 1994.

Y. Kawakami, S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini et al., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc Natl Acad Sci U S A, vol.91, issue.9, pp.3515-3519, 1994.

Y. Godet, A. Moreau-aubry, Y. Guilloux, V. Vignard, A. Khammari et al., MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency, J Exp Med, vol.205, issue.11, pp.2673-2682, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-02482029

Y. Godet, J. Desfrancois, V. Vignard, D. Schadendorf, A. Khammari et al., Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, Eur J Immunol, vol.40, issue.6, pp.1786-1794, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-02481945

E. M. Verdegaal, M. Visser, T. H. Ramwadhdoebe, C. E. Van-der-minne, J. A. Van-steijn et al., Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha, Cancer Immunol Immunother, vol.60, issue.7, pp.953-963, 2011.

N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly et al., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N Engl J Med, vol.358, issue.25, pp.2698-2703, 2008.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann et al., Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J Immunol, vol.170, issue.4, pp.2161-2169, 2003.

A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger et al., Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma, J Clin Oncol, vol.24, issue.31, pp.5060-5069, 2006.

C. Jandus, G. Bioley, D. Dojcinovic, L. Derre, L. Baitsch et al., , 2009.

, CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts, Cancer Res, vol.69, issue.20, pp.8085-8093

M. E. Dudley, J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang et al., Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma, J Immunother, vol.24, issue.4, pp.363-373, 2001.

C. M. Rooney, C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey et al., Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients, Blood, vol.92, issue.5, pp.1549-1555, 1998.

E. A. Walter, P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe et al., Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor, N Engl J Med, vol.333, issue.16, pp.1038-1044, 1995.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J Immunol, vol.160, issue.4, pp.1750-1758, 1998.

D. Valmori, J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar et al., Optimal activation of tumorreactive T cells by selected antigenic peptide analogues, Int Immunol, vol.11, issue.12, pp.1971-1980, 1999.

A. Khammari, N. Labarriere, V. Vignard, J. M. Nguyen, M. C. Pandolfino et al., Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones, J Invest Dermatol, vol.129, issue.12, pp.2835-2842, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02481977

V. Vignard, B. Lemercier, A. Lim, M. C. Pandolfino, Y. Guilloux et al., Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-Aspecific T cells, J Immunol, vol.175, issue.7, pp.4797-4805, 2005.

C. Yee, J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche et al., Adoptive T cell therapy using antigenspecific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc Natl Acad Sci U S A, vol.99, issue.25, pp.16168-16173, 2002.

J. Weber, M. Atkins, P. Hwu, L. Radvanyi, M. Sznol et al., White paper on adoptive cell therapy for cancer with tumorinfiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy, Clin Cancer Res, vol.17, issue.7, pp.1664-1673, 2011.

V. Corbiere, J. Chapiro, V. Stroobant, W. Ma, C. Lurquin et al., Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases, Cancer Res, vol.71, issue.4, pp.1253-1262, 2011.

C. Germeau, W. Ma, F. Schiavetti, C. Lurquin, E. Henry et al., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, J Exp Med, vol.201, issue.2, pp.241-248, 2005.

C. Lurquin, B. Lethe, E. De-plaen, V. Corbiere, I. Theate et al., Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, J Exp Med, vol.201, issue.2, pp.249-257, 2005.

R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang et al., Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, vol.314, issue.5796, pp.126-129, 2006.

G. M. Bendle, J. B. Haanen, and T. N. Schumacher, Preclinical development of T cell receptor gene therapy, Curr Opin Immunol, vol.21, issue.2, pp.209-214, 2009.

C. J. Cohen, Y. F. Li, M. El-gamil, P. F. Robbins, S. A. Rosenberg et al., Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond, Cancer Res, vol.67, issue.8, pp.3898-3903, 2007.

G. Bialer, M. Horovitz-fried, S. Ya'acobi, R. A. Morgan, and C. J. Cohen, Selected murine residues endow human TCR with enhanced tumor recognition, J Immunol, vol.184, issue.11, pp.6232-6241, 2010.

A. Jorritsma, R. Schotte, M. Coccoris, M. A. De-witte, and T. N. Schumacher, Prospects and limitations of T cell receptor gene therapy, Curr Gene Ther, vol.11, issue.4, pp.276-287, 2011.

M. Cobbold, N. Khan, B. Pourgheysari, S. Tauro, D. Mcdonald et al., Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers, J Exp Med, vol.202, issue.3, pp.379-386, 2005.

M. Bodinier, M. A. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat Med, vol.6, issue.6, pp.707-710, 2000.

N. Labarriere, N. Gervois, A. Bonnin, R. Bouquie, F. Jotereau et al., PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting, Cancer Immunol Immunother, vol.57, issue.2, pp.185-195, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00167752

R. Bouquie, A. Bonnin, K. Bernardeau, A. Khammari, B. Dreno et al., A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes, Cancer Immunol Immunother, vol.58, issue.4, pp.553-566, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02481983

N. Labarriere, A. Khammari, F. Lang, and B. Dreno, Is antigen specificity the key to efficient adoptive T-cell therapy?, Immunotherapy, vol.3, issue.4, pp.495-505, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02481934

G. Sarrabayrouse, M. Corvaisier, L. H. Ouisse, C. Bossard, L. Mevel et al., Tumor-reactive CD4+ CD8alphabeta+ CD103+ alphabetaT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers, Int J Cancer, vol.128, issue.12, pp.2923-2932, 2011.

M. F. Kotturi, I. Scott, T. Wolfe, B. Peters, J. Sidney et al., Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance, J Immunol, vol.181, issue.3, pp.2124-2133, 2008.

C. Alanio, F. Lemaitre, H. K. Law, M. Hasan, and M. L. Albert, Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies, Blood, vol.115, issue.18, pp.3718-3725, 2010.
URL : https://hal.archives-ouvertes.fr/pasteur-01402100

R. Offringa, Antigen choice in adoptive T-cell therapy of cancer, Curr Opin Immunol, vol.21, issue.2, pp.190-199, 2009.

L. V. Ly, M. Sluijter, M. Versluis, G. P. Luyten, S. H. Van-der-burg et al., Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm, Cancer Res, vol.70, issue.21, pp.8339-8346, 2010.